OCTAVE is a multi-disease, observational, cohort trial that will seek to understand the immune response to SARS-CoV-2 vaccinations in patients with certain immunosuppressed conditions.

Cohorts will include patients with chronic renal conditions, chronic liver conditions, inflammatory bowel disease, cancer (both solid and haematological malignancies), immune-mediated rheumatic/inflammatory conditions and haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR) T recipients. OCTAVE is a collaborative research project involving academic partners from the Universities of Glasgow, Birmingham, Oxford, Imperial College London and the IMPACT network. The project is funded by the Medical Research Council, and badged as an Urgent Public Health trial supported by the NIHR Clinical Research Network.


Contact details for the OCTAVE site

Also in 'Cancer Research UK Clinical Trials Unit'